Skip to Content

Acumen Pharmaceuticals Inc ABOS Stock Quote

| Rating as of

Morningstar‘s Stock Analysis ABOS

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics ABOS

Company Profile ABOS

Business Description

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Contact
427 Park Street
Charlottesville, VA, 22902
T +1 434 297-1000
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 17